Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Aprea Therapeutics, Inc. Common stock

APRE

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Last trade $0.4234
Day change +$0.0171 (+4.21%)
Day range $0.375 – $0.449
Volume 266,412
Market cap $6M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.82M
Price / earnings
—
Price / book
0.17×
Price / sales
1,743.59×
EV / sales
-9,597.84×
EV / EBITDA
2.1×

Profitability

Earnings per share
-$1.00
Return on assets
-36.44%
Return on equity
-41.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.67×
Quick ratio
9.67×
Cash ratio
9.52×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.74M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for APRE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$3.34K$1.85K$118.11K$162.46K$205.82K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$3.34K$1.85K$118.11K$162.46K$205.82K
Selling, general and administrative$1.83M$1.57M$1.82M$1.64M$1.48M$1.59M$1.76M$1.07M
Research and development$3.34M$2.46M$1.61M$1.01M$1.64M$1.91M$2.48M$2.36M
Total operating expenses$5.17M$4.03M$3.43M$2.65M$3.12M$3.51M$4.25M$3.43M
Operating income-$5.17M-$4.03M-$3.43M-$2.64M-$3.12M-$3.39M-$4.09M-$3.23M
Interest expense$360.7K$358.92K$134.78K$0$150.67K$178.03K$204.73K$0
Income before taxes-$4.81M-$3.59M-$3.29M-$2.46M-$2.97M-$3.24M-$3.93M-$2.89M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.81M-$3.59M-$3.29M-$2.46M-$2.97M-$3.24M-$3.93M-$2.89M
Net income attributable to common shareholders-$4.81M-$3.59M-$3.29M-$2.46M-$2.97M-$3.24M-$3.93M-$2.89M
EBITDA-$5.17M-$4.03M-$3.42M-$2.64M-$3.11M-$3.38M-$4.08M-$3.22M
Basic earnings per share-$0.09-$0.07-$0.22-$0.32-$0.47-$0.53-$0.66-$0.49
Diluted earnings per share-$0.09-$0.07-$0.22-$0.32-$0.47-$0.53-$0.66-$0.49

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Aprea Therapeutics, a clinical-stage precision medicine oncology company, announced that its President and CEO Oren Gilad will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. The company is developing targeted cancer therapies including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumors.

GlobeNewswire Inc.

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Therapeutics reported positive preclinical and early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV-positive head and neck squamous cell carcinoma. The drug showed potent single-agent activity and enhanced synergy with anti-PD-1 therapies in preclinical models, and demonstrated early disease control in a Phase 1 trial.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 13, 20231-for-20reverse split
Dec 27, 20181-for-1,000reverse split
Sep 13, 20111-for-500reverse split